22. Moyamoya disease Clinical trials / Disease details
Clinical trials : 17 / Drugs : 22 - (DrugBank : 17) / Drug target genes : 33 - Drug target pathways : 45
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100046178 | 2021-05-10 | 2021-05-08 | Efficacy and safety of antiplatelet drugs in patients with moyamoya disease after revascularization | Efficacy and safety of antiplatelet drugs in patients with moyamoya disease after revascularization | Moyamoya disease | Taking aspirin group:Nil;No aspirin group:Nil; | Qilu Hospital of Shandong University | NULL | Recruiting | 0 | 60 | Both | Taking aspirin group:105;No aspirin group:105; | china | |
| 2 | NCT04012268 (ClinicalTrials.gov) | July 15, 2019 | 3/7/2019 | The Safety and Efficacy of RIC on Adult Moyamoya Disease | The Safety and Effect of Remote Ischemic Conditioning on Adult Moyamoya Disease | Moyamoya Disease | Device: RIC;Drug: Aspirin | Capital Medical University | NULL | Completed | 18 Years | 60 Years | All | 30 | N/A | China |
| 3 | ChiCTR1800020377 | 2019-01-01 | 2018-12-27 | Aspirin in Moyamoya Disease | The Clinical Benefit and Risk of Oral Aspirin for Moyamoya Disease | moyamoya disease | Case series:Aspirin; | Beijing Tiantan Hospital, Capital Medical University | NULL | Recruiting | 8 | 60 | Both | Case series:300; | China |